Skip Search
For exact phrase add quotation marks
page content
Skip page content
Type I Diabetes Control
DreaMed Diabetes, Schneider Children’s, and the John A. Paulson School for Engineering and Applied Sciences (SEAS) at Harvard University, will collaborate to improve Type I Diabetes care
Date: 10.05.17 | Update: 22.05.17

DreaMed Diabetes, a company that develops solutions for the management and care of diabetes, Schneider Children’s Medical Center, and researchers at the John A. Paulson School for Engineering and Applied Sciences (SEAS) at Harvard University, have signed a cooperative agreement to improve the management of insulin levels for people with Type I Diabetes. Researchers from DreaMed will collaborate with Dr. Eyal Desau, principle investigator in medical engineering, Francis J. Doyle III, Dean of SEAS, and Prof. Moshe Phillip and Dr. Revital Nimri of Schneider Children’s in order to increase the possibilities for people with Type I Diabetes who receive a number of insulin injections daily and use a home glucose monitor.

Eran Atlas, CEO of DreaMed, noted that “due to various reasons, a large percentage of people with Diabetes Type I, do not use an insulin pump and a continuous glucose monitor, but rely on a glucometer and insulin injections. Today, there is no data about the habits of insulin injections in this population. In the era of “smart” and online devices, where insulin injections can be registered on mobile phones of patients and the data collected on established cloud platforms, we can take advantage of the opportunity to gather precise data from the majority of diabetics in order to develop a product that will allow them to better control their disease.” 

Prof. Phillip             


Dr. Desau said that “our studies of automatic algorithms to manage insulin and to evaluate the clinical efficiency of this new technology will allow us to develop new systems for managing the insulin dosage for patients who are treated with short-term multiple daily injections (MDI), and to improve the level of care for many people who do not use an insulin pump.”

Prof. Doyle III added that “this collaboration represents many years of attempts to develop algorithms to automatically control the level of glucose in the blood, known sometimes as the artificial pancreas system, in addition to broad clinical validation.”

Prof. Moshe Phillip, Chair and Principle Scientist of DreaMed Diabetes, and Director of the Institute of Endocrinology and Diabetes at Schneider Children’s, explained that “patients with Type I Diabetes who receive MDIs and their care-givers, rely on personal information that includes accumulated data about past glucose and insulin levels, as well as detailed information concerning the amount and times of meals and level of physical activity. Analysis of this data takes time and demands immense skill. Additionally, the reports from the viewpoint of most patients with Diabetes Type I, do not succeed in reaching the control targets of recommended glucose levels. Therefore, there is a need to develop other tools and algorithms to assist both doctors and patients improve the profile of glucose control in the Diabetes Type I population.”

About Glucose Level Control
Insulin-dependent diabetes is a growing global problem that affects more than 90 million people around the world. Blood glucose levels must be controlled as it is the main cause of severe complications of diabetes. Despite the progress made in insulin treatment and glucose measurement devices, most patients do not reach the stipulated glucose level targets leaving them vulnerable to chronic and costly complications. Insulin-dependent patients represent about 50% of the diabetics worldwide, which grows by about 6% annually.

About DreaMed Diabetes
DreaMed Diabetes was founded in 2014, and develops healthy solutions and tools to support decision-making through the use of optimal algorithms for insulin treatment to benefit both Type I and Type II diabetics. The first product of the company, GlucoSitterTM, was developed for closed systems for insulin care, for which patent rights were obtained by Meditronic. The new device of the company, AdvisorTM, is an automated system for insulin treatment individually programmed for the patient. For further information, kindly visit the site

About Schneider Children’s Medical Center of Israel
Schneider Children’s is the only one of its kind in Israel and the Middle East, which provides the full range of pediatric services under one roof. Since its inception in 1991, Schneider Children’s has revolutionized pediatric care in Israel and is known as one of the leading pediatric institutions in the world. The Institute of Endocrinology and Diabetes, is a national center for referrals, and the first to apply an all-encompassing, multidisciplinary approach for the treatment of diabetes in Israel. The Institute treats children and youth suffering from hormonal or growth problems and follows about 1,700 Type I diabetes patients. The Institute has won worldwide acclaim due to its introduction of new approaches in the treatment of childhood diabetes, and manages technological projects related to diabetes, included the artificial pancreas and a support system for decision-making that will revolutionize the treatment of diabetes in the future.

About the John A. Paulson School of Engineering and Applied Sciences (SEAS)
SEAS serves as the unifying bridge between the arms of teaching and research at Harvard in the field of engineering, applied sciences and technology. Through collaboration with researchers in all departments at Harvard and other universities, the through business partners and institutions, we promote discoveries and developments to directly influence the quality of life of the individual and society.

Jump to page content